Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposome Combo in 1L mCRC
NCT06225622Phase 1Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Mar 2024
- Primary completion
- Jan 2026
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of irinotecan liposome injection in metastatic colorectal cancer (mCRC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Maximum-tolerated dose at 14 days and Treatment-related adverse events. Started Mar 2024; status: recruiting.
02
Drugs
irinotecan liposome injection
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06225622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06225622.